Jade Biosciences, Inc. Capital Expenditures Incurred but Not yet Paid
Jade Biosciences, Inc. (JBIO) reported Capital Expenditures Incurred but Not yet Paid of $16.00 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-10
- Jade Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $11.00K.
- Jade Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $5.00K.
- Jade Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $30.00K, a 64.71% decline year-over-year.
- Jade Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-03-31 was $85.00K.
- Jade Biosciences, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $21.00K, a 47.50% decline from fiscal 2020.
- Jade Biosciences, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $40.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2025-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $16.00K 10-Q · filed 2026-08-10 | ||
| 2025-03-31 | $5.00K 10-Q · filed 2026-05-07 | |||
| 2023-09-30 | $64.00K 10-Q · filed 2024-11-12 | |||
| 2023-03-31 | $30.00K 10-Q · filed 2024-05-13 | |||
| 2022-09-30 | $34.00K 10-Q · filed 2023-11-13 | |||
| 2022-03-31 | $85.00K 10-Q · filed 2023-05-15 | $72.00K derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2021-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $21.00K 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $34.00K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $40.00K 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |